DUBLIN--(BUSINESS WIRE)--Nov 9, 2022--
The "North America Genotyping Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product and Services, Technology, Application, and End User" report has been added to ResearchAndMarkets.com's offering.
The genotyping market in North America is expected to grow from US$ 11,734.10 million in 2022 to US$ 37,599.28 million by 2028. It is estimated to grow at a CAGR of 21.4% from 2022 to 2028.
Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases, such as cancer, diabetes, and Alzheimer's.
Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification.
Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Since these conditions are difficult to identify clinically, genotyping is the backbone of diagnostic testing in the population. This rising adoption of prenatal genetic screening to examine children's chromosomal anomalies could prove to be a significant driving factor.
Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves.
More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases across the region will act as one of the key factors driving the growth of the genotyping markets.
North America Genotyping Market Segmentation
The North America genotyping market is segmented by products and services, technology, application, end user, and country.
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Future Trends
Key Topics Covered:
1. Introduction
2. North America Genotyping Market - Key Takeaways
3. Research Methodology
4. North America Genotyping Market - Market Landscape
5. North America Genotyping Market- Key Market Dynamics
6. Genotyping Market- North America Analysis
7. North America Genotyping Market- by Product and Services
8. North America Genotyping Market- by Technology
9. North America Genotyping Market-by Application
10. North America Genotyping Market- by End User
11. North America Genotyping Market- Country Analysis
12. North America Genotyping Market Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/y6m0ne
View source version on businesswire.com:https://www.businesswire.com/news/home/20221109005635/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/09/2022 08:05 AM/DISC: 11/09/2022 08:06 AM
http://www.businesswire.com/news/home/20221109005635/en